LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Articles
Immunai Inc.
Headquarters:
New York, NY, United States of America
Website:
https://www.immunai.com/
Year Founded:
2018
Status:
Private
BioCentury
|
Mar 7, 2025
Management Tracks
Abbas Kazimi succeeds Jeb Keiper as CEO of Nimbus
Plus: Jon Garay Alonso named CFO of Almirall, and updates from Certara and Immunai
Read More
BioCentury
|
Apr 18, 2024
Management Tracks
Protego names Warner CEO
Plus: Foghorn hires Humer and updates from Javelin, Stoke, Sensorium, Theradaptive and more
Read More
BioCentury
|
Oct 28, 2021
Deals
Oct. 27 Quick Takes: Advancing ‘atlas’ of immunology, Immunai raises $215M
Plus Teva and Modag partner, Fosun, Novavax and DBV
Read More
BioCentury
|
Feb 12, 2021
Deals
Feb. 11 Quick Takes: First day pop for Bioventus; plus venture rounds for Pipeline, Immunai, Sanofi, i2O, AZ’s trimmings, Truveta
Shares of Bioventus Inc. (NASDAQ:BVS) rose 48% to $19.21 in its first day of trading after raising $104 million in an IPO through the sale of 8 million shares at $13. $80M series C for Versant-grown
Read More
Items per page:
10
1 - 4 of 4